Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €445.10 EUR
Change Today 0.00 / 0.00%
Volume 0.0
As of 5:30 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

54, Rue La Boétie

Paris, 75008

France

Phone: 33 1 53 77 40 00

Fax: 33 1 53 77 42 96

commercialized in the U.S. for children over 6 months, adolescents and adults. Fluzone Quadrivalent/ FluQuadri vaccine was launched in 2014 in various other countries, including Mexico and Canada. Intradermal (ID) trivalent influenza vaccines (Intanza/IDflu launched in Australia, Canada, the E.U. and various other countries and Fluzone ID launched in the U.S.) also contribute to Sanofi Pasteur's flu differentiation strategy. In 2014 Fluzone ID Quadrivalent was approved by the FDA for commercialization in the U.S. Adult and Adolescent Boosters Adacel, the first trivalent adolescent and adult booster offering protection against diphtheria, tetanus and pertussis, is licensed and launched in the U.S. Adacel is registered in approximately 60 countries. Repevax (also marketed under the trademark Adacel-Polio) is a combination vaccine that provides the same benefits as Adacel along with offering protection against polio. Repevax is useful in markets that recommend adolescent and/or adult immunizations to protect against both pertussis and polio. This vaccine is licensed in approximately 30 countries worldwide. Meningitis and Pneumonia Vaccines Sanofi Pasteur offers Menactra, the first quadrivalent conjugate vaccine against meningococcal meningitis, which is considered as the deadliest form of meningitis in the world. Menactra is indicated for people aged 9 months through 55 years in the U.S., Canada, Saudi Arabia, and various countries in Latin America, the Middle East, and the Asia Pacific regions. Travel and Endemic Vaccines Sanofi Pasteur provides a range of travel and endemic vaccines, including hepatitis A, typhoid, cholera, yellow fever, and Japanese encephalitis, as well as rabies vaccines and immunoglobulins. These vaccines and immunoglobulins are used in endemic settings in the developing world and are the foundation for important partnerships with governments and organizations, such as United Nations Children's Fund. They are also used by travelers and military personnel in industrialized countries and in endemic areas. Shantha offers Shanchol, the first oral cholera vaccine produced in India for use in children and adults. IMOJEV, a Japanese encephalitis vaccine, is the most recent addition to the company’s travel and endemic vaccines portfolio and is launched in Australia and Thailand. In 2014, IMOJEV obtained an extension of indication for use in children from nine months of age and obtained World Health Organization prequalification, which provides access to the products in low-income countries. IMOJEV is being progressively rolled out in endemic countries throughout Asia. Other Products Growth in other products is mainly driven by VaxServe, a major specialty distributor in the U.S. market. VaxServe, a Sanofi Pasteur company, offers a portfolio of products from Sanofi Pasteur and other manufacturers, and is a strategic asset that enables the company to be closer to its customers and serve their needs. Animal Health: Merial Merial engages in the research, development, manufacture and marketing of pharmaceutical products and vaccines used by veterinarians, farmers and pet owners. Merial offers a range of products to improve the health, well-being and performance of a range of animals, both production and companion. The range of veterinary products covers four major segments, such as parasiticides, anti-infectious drugs, other pharmaceuticals (such as anti-inflammatory agents, anti-ulcer agents, etc.), and vaccines. Merial's major products are Frontline, a topical anti-parasitic flea and tick brand for dogs and cats; Heartgard, a parasiticide for control of heartworm in companion animals; Nexgard, an oral anti-parasitic for the treatment and prevention of fleas and ticks in dogs; Ivomec, a parasiticide for the control of internal and external parasites in livestock; Vaxxitek, a high-technology vector vaccine, protecting chickens against infectious bursal disease and Marek's disease; Previcox, a highly selective anti-inflammatory/COX-2 inhibitor for relief of pain and control of inflammation in dogs; Eprinex, a parasiticide for use in production animals; and Circovac, a por

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHPP:FP €445.10 EUR 0.00

RHPP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $62.41 USD -1.57
Amgen Inc $151.78 USD -4.11
Bayer AG €116.85 EUR -3.68
Medtronic PLC $72.29 USD -1.27
Novo Nordisk A/S kr361.90 DKK -7.30
View Industry Companies
 

Industry Analysis

RHPP

Industry Average

Valuation RHPP Industry Range
Price/Earnings 24.2x
Price/Sales 3.2x
Price/Book 2.0x
Price/Cash Flow 16.0x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-TITR PART10%87, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.